Today: 30 June 2026

Praxis Precision Medicines (PRAX) Soars on FDA Momentum and 760-Dollar Target: December 9, 2025 Stock Deep Dive

Praxis Precision Medicines (PRAX) Soars on FDA Momentum and 760-Dollar Target: December 9, 2025 Stock Deep Dive

Praxis Precision Medicines, Inc. has turned into one of 2025’s most dramatic biotech stories. On December 9, 2025, the stock is trading around $265–270 per share, near its 52‑week high of about $278 and far above its low near $26.70, giving the company a market capitalization of roughly $6.6 billion.StockAnalysis+1 Behind that move is a mix of powerful late‑stage clinical data, accelerating FDA interactions, increasingly aggressive analyst targets — including a new $760 price target from Guggenheim — and a growing cloud of controversy after a short‑seller attack on Praxis’s lead program.Quiver Quantitative+2Investing.com+2
9 December 2025
·
XRP Price Today, December 9, 2025: Can ETFs, Wall Street Money and the Fed Push Ripple Back Above $2.50?

XRP Price Today, December 9, 2025: Can ETFs, Wall Street Money and the Fed Push Ripple Back Above $2.50?

XRP is trading just above $2.00 today, holding a key psychological level as traders weigh massive ETF inflows, Ripple’s new US$500 million Wall Street funding round, and a crucial Federal Reserve meeting that could reshape liquidity across global markets. 99Bitcoins+1 Below is a full breakdown of XRP’s price today, the latest news, and what fresh forecasts from analysts and AI models are saying right now.
9 December 2025
·
Top US Stock Market Losers Today (December 9, 2025): HURA, Phreesia, Virgin Galactic, SLM, Gogo and More

Top US Stock Market Losers Today (December 9, 2025): HURA, Phreesia, Virgin Galactic, SLM, Gogo and More

The US stock market spent most of Tuesday, December 9, 2025 trading quietly ahead of this week’s Federal Reserve decision — but beneath the calm index surface, several individual stocks suffered brutal double‑digit losses. As of around 3:44 p.m. ET, live data from Public.com showed TuHURA Biosciences, Phreesia, Euda Health, SLM Corp, Virgin Galactic, Gogo, Compass Minerals, Workhorse Group, 3D Systems and Dyne Therapeutics among the steepest percentage decliners across US‑listed stocks. Public
9 December 2025
··········
Bitcoin Price Today, December 9, 2025: BTC Holds $90K as Standard Chartered Slashes Target and Fed Rate Cut Looms

Bitcoin Price Today, December 9, 2025: BTC Holds $90K as Standard Chartered Slashes Target and Fed Rate Cut Looms

Bitcoin is trading tightly around the psychologically crucial $90,000 mark on Tuesday, December 9, 2025, as traders digest a fresh downgrade from Standard Chartered, a sharply divided set of long‑term price forecasts, and a high‑stakes Federal Reserve rate decision due tomorrow. Across major exchanges, Bitcoin is hovering in the $90,000–$91,000 range, down roughly 1–2% over the past 24 hours but still up around 3–4% on the week. CryptoPotato+4Cryptonews+4Finbold+4
9 December 2025
··
Avaada Group, GRIDCO and IIT Bhubaneswar to Set Up Green Hydrogen Center of Excellence in Odisha

Avaada Group, GRIDCO and IIT Bhubaneswar to Set Up Green Hydrogen Center of Excellence in Odisha

Bhubaneswar / New Delhi, December 9, 2025 — India's green hydrogen ambitions received a fresh boost today as Avaada Group, state utility GRIDCO and the Indian Institute of Technology Bhubaneswar formalized plans to create a Green Hydrogen Center of Excellence in Odisha. The new center will act as a dedicated hub for research, innovation and technology development across the green hydrogen value chain.Replay+ 2PV Magazine India+ 2 The move comes under the umbrella of the National Green Hydrogen Mission and aligns with the Odisha Renewable Energy Policy 2022, which aims to position the coastal state as a major clean‑energy and green fuels hub.PV Magazine India+ 1
9 December 2025
Top Gainers on the US Stock Market Today (December 9, 2025): AFJK, NCPL, XCUR, ALEX and More Surge as Fed Meeting Looms

Top Gainers on the US Stock Market Today (December 9, 2025): AFJK, NCPL, XCUR, ALEX and More Surge as Fed Meeting Looms

US stocks spent Tuesday in a cautious, sideways mood as traders waited for the Federal Reserve’s final interest‑rate decision of 2025. The Dow inched higher, the S&P 500 was roughly flat, and the Nasdaq drifted slightly lower, even as expectations hardened around another rate cut and a closely watched press conference from Fed Chair Jerome Powell. Investopedia+3StockAnalysis+3Yahoo Finance+3 Beneath the calm surface of the major indices, however, a cluster of small‑ and mid‑cap names exploded higher, posting double‑ and even triple‑digit gains on deal news, biotech data, SPAC extensions, and debt‑restructuring headlines.
9 December 2025
·
Canada Stock Market Today, December 9, 2025: TSX Climbs as Gold Stocks Rally Ahead of Fed and Bank of Canada Decisions

Canada Stock Market Today, December 9, 2025: TSX Climbs as Gold Stocks Rally Ahead of Fed and Bank of Canada Decisions

Toronto’s S&P/TSX Composite Index finished higher on Tuesday, December 9, 2025, as gold miners, utilities and heavyweight financials led gains while investors braced for back‑to‑back interest‑rate decisions from the U.S. Federal Reserve and the Bank of Canada on Wednesday. According to daily data from Investing.com, the S&P/TSX Composite Index closed at 31,328.16, up around 158 pointsfrom Monday’s close of 31,169.97 — a gain of roughly 0.5% on the day. The benchmark traded between 31,160.89 and 31,340.32 after opening at 31,164.86, with volume just over 37 million shares. Investing.com
9 December 2025
······
Silver Price Today, December 9, 2025: XAG/USD Near $60 as Fed Rate Cut Bets and Supply Squeeze Drive Fresh Rally

Silver Price Today, December 9, 2025: XAG/USD Near $60 as Fed Rate Cut Bets and Supply Squeeze Drive Fresh Rally

Silver prices are surging again today, with spot XAG/USD trading around $60 per ounce and hovering just below this month’s record highs as traders brace for a pivotal U.S. Federal Reserve decision and an increasingly severe physical supply squeeze. Live wholesale quotes from bullion dealers show silver near $60.05/oz, up about 2.9% on the day as of 10:37 a.m. ET, after earlier trading in the high‑$57s to high‑$58s. JM Bullion+1 At the same time, silver remains one of 2025’s standout assets globally: it has roughly doubled in price this year, with some datasets putting year‑to‑date gains around 100–102%, far outpacing gold’s roughly 60% rise. Reuters+2Investopedia+2
9 December 2025
···
US Stock Market Today, December 9, 2025: Wall Street Pauses as Fed Rate Cut Decision Nears

US Stock Market Today, December 9, 2025: Wall Street Pauses as Fed Rate Cut Decision Nears

Wall Street is in “wait-and-see” mode on Tuesday, December 9, 2025, with major US stock indices trading in a tight range as the Federal Reserve begins its final policy meeting of the year and investors digest fresh labor market data and big corporate headlines. By late morning in New York, the Dow Jones Industrial Average and S&P 500 were modestly higher, while the Nasdaq Composite hovered slightly in the red, leaving all three benchmarks still close to record territory after Monday’s small pullback. Reuters+2Investopedia+2
9 December 2025
·
UK Stock Market Today (9 December 2025): FTSE 100 Edges Higher as Defence Stocks Offset BAT Slide

UK Stock Market Today (9 December 2025): FTSE 100 Edges Higher as Defence Stocks Offset BAT Slide

The UK stock market spent Tuesday moving in a narrow band but ultimately closed modestly higher, as defence stocks helped the FTSE 100 overcome weakness in tobacco and consumer names ahead of crucial interest rate decisions from the US Federal Reserve and the Bank of England. By early afternoon in London, the FTSE 100 was up around 0.1%, with the domestically focused FTSE 250 gaining about 0.2%, helped by strong defence shares and despite pressure on British American Tobacco. Reuters+1
9 December 2025
····
Dyne Therapeutics (DYN) Stock Slides After $300 Million Offering as Duchenne Trial Data Drives Bullish Street Targets

Dyne Therapeutics (DYN) Stock Slides After $300 Million Offering as Duchenne Trial Data Drives Bullish Street Targets

December 9, 2025 — Dyne Therapeutics, Inc. shares were volatile on Tuesday, giving back part of a recent rally even as Wall Street responded positively to new clinical data and raised price targets on the neuromuscular‑disease biotech. In early afternoon U.S. trading, Dyne stock was changing hands around $19.15, down roughly 14% on the day after opening near $21.41 and moving in a range between about $19 and $22. The pullback follows a sharp advance on Monday, when the shares jumped high‑single‑digits after the company released detailed positive Phase 1/2 results from its DELIVER trial in Duchenne muscular dystrophy. StockInvest+3GlobeNewswire+3Nasdaq+3
9 December 2025
··
Eli Lilly (LLY) Stock on December 9, 2025: Jaypirca Breakthrough, Adverum Deal and Zepbound Price Cuts Reframe the Outlook

Eli Lilly (LLY) Stock on December 9, 2025: Jaypirca Breakthrough, Adverum Deal and Zepbound Price Cuts Reframe the Outlook

Eli Lilly and Company is once again in the spotlight. As of early trading on December 9, 2025, Eli Lilly stock is hovering around $997 per share, roughly 10% below its late‑November all‑time high but still up about 30% year to date and about 25% over the past 12 months.FinanceCharts Today’s story is about more than the share price: fresh Phase 3 cancer data for Jaypirca, the completed acquisition of Adverum, a higher 2026 dividend, Nobel laureate Carolyn Bertozzi rejoining the board, and an ongoing price reset for blockbuster obesity drug Zepbound. Together they reshape how investors are thinking about Eli Lilly’s growth, risk, and valuation.Reuters+4PR Newswire+4PR Newswire+4
9 December 2025
Arrowhead Pharmaceuticals (ARWR) Stock Soars on First FDA Approval, Novartis Deal and New Alzheimer’s Trial

Arrowhead Pharmaceuticals (ARWR) Stock Soars on First FDA Approval, Novartis Deal and New Alzheimer’s Trial

Arrowhead Pharmaceuticals, Inc. is ending 2025 in rare biotech air. The RNA interference specialist has secured its first U.S. drug approval, locked in a multibillion‑dollar licensing deal with Novartis, and just dosed the first subjects in a new Alzheimer’s disease trial — all while its share price hovers near record highs. Arrowhead Pharmaceuticals, Inc.+2Arrowhead Pharmaceuticals+2 As of intraday trading on December 9, 2025, Arrowhead Pharmaceuticals stock trades around $69 per share, giving the company a market value in the $9–9.5 billion range. That’s up dramatically from under $10 per share at its 52‑week low, and represents a triple‑digit gain over the past year and roughly 260–270% year‑to‑date, depending on the data source. Yahoo Finance+2Investing.com+2
9 December 2025
··
Robinhood (HOOD) Stock Today: Price, Latest News, Crypto Expansion and 2026 Forecasts

Robinhood (HOOD) Stock Today: Price, Latest News, Crypto Expansion and 2026 Forecasts

As of December 9, 2025, Robinhood Markets, Inc. is trading around $136 per share, giving the online broker a market capitalization in the $120–$125 billion range and a price-to-earnings ratio near 56–58.MarketBeat The stock has been one of the best-performing names in the S&P 500 in 2025. NerdWallet data shows Robinhood leading the index with a ~240% one‑year return and roughly 243% year‑to‑date gain as of early December, far ahead of other top performers like Western Digital and Palantir.NerdWallet Other analyses put its 2025 gain closer to 260–270%, reflecting continued momentum into December.Ticker Nerd+1
9 December 2025
··
CoreWeave (CRWV) Stock Today: Debt, AI Cloud Growth, and What the $2.25 Billion Convertible Notes Mean for 2026

CoreWeave (CRWV) Stock Today: Debt, AI Cloud Growth, and What the $2.25 Billion Convertible Notes Mean for 2026

CoreWeave, Inc. has become one of the most closely watched AI infrastructure stocks of 2025. As of December 9, 2025, the Nvidia-backed “AI hyperscaler” is back in the spotlight after pricing an upsized $2.25 billion convertible senior notes offering, deepening investor debate over whether CoreWeave is a visionary AI cloud leader or a debt-fueled accident waiting to happen. Stock Titan+1 Below is a detailed look at CoreWeave stock today, the latest news, its balance sheet, growth story, and how analysts and commentators are thinking about the CRWV stock outlook into 2026.
9 December 2025
··
Carvana Stock (CVNA) Soars on S&P 500 Inclusion: Latest Price, News, Analyst Forecasts and Risks as of December 9, 2025

Carvana Stock (CVNA) Soars on S&P 500 Inclusion: Latest Price, News, Analyst Forecasts and Risks as of December 9, 2025

Carvana’s stock has gone from near‑bankruptcy meme to S&P 500 heavyweight in under three years, and as of December 9, 2025, the story is still accelerating. Shares of Carvana Co. are trading around $450 in today’s session, hovering near all‑time highs after the company was selected for inclusion in the S&P 500 index effective December 22, 2025. Investing.com
9 December 2025
··
Intel Stock Outlook December 2025: AI Wafers Shortage, Tata Deal and U.S. Government Stake Reshape INTC

Intel Stock Outlook December 2025: AI Wafers Shortage, Tata Deal and U.S. Government Stake Reshape INTC

Intel Corporation has quietly become one of 2025’s most dramatic comeback stories. After losing nearly $19 billion in 2024, the chipmaker has returned to profitability, installed a new CEO, secured multibillion‑dollar backing from the U.S. government, SoftBank and Nvidia, and ridden the AI‑PC wave to a triple‑digit share‑price gain.NVIDIA Newsroom+4Reuters+4Reuters+4 As of midday on December 9, 2025, Intel stock trades around $40.30, giving the company a market value near $172 billion. Over the past 52 weeks, INTC has traded between $17.66 and $44.02, and has delivered roughly 101% total return year‑to‑date, far outpacing the S&P 500’s mid‑teens gain.StockAnalysis
9 December 2025
·
Warby Parker (WRBY) Soars on Google AI Glasses News: Is the Stock a Buy After December 2025’s Rally?

Warby Parker (WRBY) Soars on Google AI Glasses News: Is the Stock a Buy After December 2025’s Rally?

Warby Parker Inc. has suddenly gone from sleepy eyewear retailer to one of the market’s more intriguing AI-adjacent stories. On December 8–9, 2025, Warby Parker shares spiked more than 13–16% in heavy trading, climbing from the high teens to around $22–23 per share, after Google publicly confirmed that its first pair of AI-powered glasses co-developed with Warby Parker is slated to launch in 2026.Reuters+1
9 December 2025
···
1 … 1,522 1,523 1,524 1,525 1,526 … 2,122

Stock Market Today

  • Telix Pharmaceuticals (ASX:TLX) tops Australian growth stocks with large insider holdings
    June 30, 2026, 3:11 AM EDT. Telix Pharmaceuticals (ASX:TLX) is at the front of Australian growth stocks with high insider ownership, seen as a sign of management confidence. The biopharma group, focused on radiopharmaceuticals in cancer imaging and care, pulled in about US$803.8 million in sales, most of that coming from the U.S. The company's market cap stands at A$5.5 billion. Telix's cancer pipeline is broad, and its commercial footing is firm. Its key products, Illuccix and Gozellix, support 2026 revenue targets of US$950-970 million. There's still risk from regulatory and pricing pressure, but insiders remain aligned, and partnerships with United Imaging and Regeneron support the growth story. Also mentioned: Lindian Resources (ASX:LIN), market cap A$1.7 billion, which is pushing ahead on a rare earths project in Malawi. Both names show that shareholder interest tracks with insider backing.
Go toTop